UK-based charity Cancer Research has selected Onyx Scientific, a manufacturer of active pharmaceutical ingredients (APIs), to participate in a major drug development and manufacturing project.
Onyx Scientific has been chosen to develop the chemistry and perform the GMP synthesis of the API for use in a Phase 1 clinical trial.
The Cancer Research UK team initially approached its preferred suppliers with its requirements and a proposed development route.
After analysing the charity's needs in more detail, the technical team at Onyx Scientific has improved the synthetic methodology as well as suggesting an alternative route, which, in the long term, will potentially help make the project more efficient and cost effective.
